Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 4Phase NA 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Colorectal Neoplasms 39Pancreatic Neoplasms 27Rectal Neoplasms 21Stomach Neoplasms 20Colonic Neoplasms 16Esophageal Neoplasms 11Neoplasm Metastasis 7Lymphoma, Large B-Cell, Diffuse 7Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Liver Neoplasms 4Cholangiocarcinoma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Prolymphocytic 2Glioblastoma 2Gastrointestinal Diseases 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Oxaliplatin × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡